Chinook Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2023 to a ratio of 2.45, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2023. Average receivable collection period, for the Chinook Therapeutics Inc in Jun 30 2023 quarter, has decreased to 149 days, compared to 166 days, in the Mar 31 2023 quarter.

If we take a look into Healthcare sector 638 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2023 from 4075 to 4144.

What is Receivable Turnover Ratio?
What is Chinook Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

KDNY Receivables Turnover Ratio	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter	(Jun 30 2022) II. Quarter
Y / Y Receivable Change	-0.42 %	-17.07 %	-89.16 %	26436.36 %	567.02 %
Y / Y Revenue Change	141.15 %	-32.22 %	-99 %	62425 %	1129.41 %
Receivable Turnover Ratio (TTM)	2.45	2.2	2.43	11.94	13.48
KDNY's Total Ranking	# 4144	# 4075	# 3537	# 3442	# 3126
Accounts Receivable average collection period days	149	166	150	31	27
Seq. Receivable Change	26.92 %	124.01 %	-62.62 %	-6.29 %	5.7 %
Seq. Revenue Change	-44.86 %	257.03 %	-79.53 %	498.33 %	-84.5 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 247
Healthcare Sector	# 639
Overall Market	# 4144

Receivable Turnover Ratio Statistics
High	Average	Low
0.12	0.05	-0.05
(Dec 31 2021)		(Sep 30 2021)

KDNY Company Profile • Back to KDNY Efficiency Comparisons • Compare KDNY Receivables Turnover Ratio to its Competitors

Financial Statements
Chinook Therapeutics Inc 's Accounts Receivable	$ 3 Millions	Visit KDNY's Balance sheet
Chinook Therapeutics Inc 's Sales TTM	$ 6 Millions	Visit KDNY's Income Statement
Sources of KDNY's Revenues		Visit KDNY's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
KDNY's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
KDNY's Growth Rates	KDNY's Roa	KDNY's Inventory Turnover Ratio	KDNY's Dividend Comparisons
KDNY's Profitability Ratios	KDNY's Roi	KDNY's Asset Turnover Ratio	KDNY's Dividend Growth
KDNY's Valuation Ratios	KDNY's Roe	KDNY's Financial Strength Ratios	KDNY's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2023, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2023	Receivable at quarter ending Jun 30 2023
Caremax Inc	5.18	$ 719.356 Millions	$ 138.901 Millions
Psychemedics Corporation	5.17	$ 23.137 Millions	$ 4.478 Millions
Mersana Therapeutics inc	5.16	$ 38.717 Millions	$ 7.500 Millions
Tenon Medical Inc	5.15	$ 1.661 Millions	$ 0.322 Millions
Tactile Systems Technology Inc	5.15	$ 266.307 Millions	$ 51.681 Millions
Guardion Health Sciences Inc	5.15	$ 9.399 Millions	$ 1.825 Millions
Iradimed Corporation	5.15	$ 59.876 Millions	$ 11.635 Millions
Therapeutic Solutions International Inc	5.14	$ 0.133 Millions	$ 0.026 Millions
Sonoma Pharmaceuticals Inc	5.14	$ 12.716 Millions	$ 2.476 Millions
Avanos Medical Inc	5.12	$ 780.100 Millions	$ 152.275 Millions
Alkermes Plc	5.09	$ 1,462.023 Millions	$ 287.199 Millions
Inhibikase Therapeutics Inc	5.09	$ 0.252 Millions	$ 0.049 Millions
Labcorp Holdings Inc	5.08	$ 14,091.900 Millions	$ 2,773.150 Millions
Cardiff Oncology Inc	5.07	$ 2.863 Millions	$ 0.565 Millions
Cryo cell International Inc	5.05	$ 31.042 Millions	$ 6.149 Millions
Agilent Technologies inc	5.04	$ 6,994.000 Millions	$ 1,387.500 Millions
Biorestorative Therapies Inc	5.04	$ 0.129 Millions	$ 0.026 Millions
Kewaunee Scientific Corporation	5.02	$ 218.285 Millions	$ 43.501 Millions
Exagen Inc	5.01	$ 52.930 Millions	$ 10.564 Millions
Butterfly Network Inc	5.01	$ 72.323 Millions	$ 14.437 Millions
Cvrx inc	5.01	$ 29.984 Millions	$ 5.990 Millions
Caredx Inc	5.00	$ 309.306 Millions	$ 61.918 Millions
Abbvie Inc	4.98	$ 56,023.000 Millions	$ 11,240.250 Millions
2seventy Bio Inc	4.98	$ 147.254 Millions	$ 29.587 Millions
Ptc Therapeutics inc	4.97	$ 818.730 Millions	$ 164.860 Millions
Procept Biorobotics Corporation	4.96	$ 101.634 Millions	$ 20.481 Millions
Organogenesis Holdings Inc	4.96	$ 456.333 Millions	$ 92.050 Millions
Skinhealth Systems Inc	4.95	$ 390.079 Millions	$ 78.789 Millions
Lantheus Holdings Inc	4.95	$ 1,124.942 Millions	$ 227.264 Millions
Orthopediatrics Corp	4.91	$ 137.091 Millions	$ 27.918 Millions

Date modified: 2026-08-29T17:18:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.